The lack of pathological neovascularisation in treatment with epoetin delta is therefore unexpected, especially since it has been demonstrated that raised endogenous EPO levels are associated with proliferative diabetic retinopathy [20], [39]. This evidence concerns the gene EPO and proliferative diabetic retinopathy.